Hesperos Inc.
Andrew Antolic is a Laboratory Facilities and Operations Manager at Hesperos Inc. since December 2022, with prior experience at Emory University School of Medicine where significant contributions were made as a Project Lead on various cardiac research projects. Notable projects included exploring the role of NOX4 in cardiac fibrosis, characterizing GDF15 as a myocardial hormone in heart failure, and investigating epigenetic activation of cardiac fibroblasts. Andrew also has experience in maternal/fetal cardiac health from the University of Arizona and the University of Florida College of Pharmacy, where responsibilities included curriculum development and student mentorship. Educational qualifications include a PhD in Fetal Cardiac Physiology from the University of Florida, a Master of Public Health from Saint Louis University, and a Bachelor's in Biology from the University of Florida.
This person is not in any teams
Hesperos Inc.
Hesperos, Inc. is a leader in efforts to characterize an individual's biology with Human-on-a-Chip microfluidic systems. Founders Michael L. Shuler and James J. Hickman have been at the forefront of every major scientific discovery in this realm, from individual organ-on-a-chip constructs to fully functional, interconnected multi-organsystems. With a mission to revolutionize toxicology testing as well as efficacy evaluation for drug discovery, the company has created pumpless platforms with serum-free cellular mediums that allow multi-organ system communication and integrated computational PKPD modeling of live physiological responses utilizing functional readouts from neurons, cardiac, muscle, barrier tissues and neuromuscular junctions as well as responses from liver, pancreas and barrier tissues.